

ABSTRACT OF THE DISCLOSURE

The present invention discloses the use of high affinity adenosine A₃ receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A₃ receptors and cancers expressing P-glycoprotein or MRP. In preferred
5 embodiments, adenosine A₃ receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or antibiotic chemotherapeutic agent.

339812.1